Search results for "aav"
Article
How to develop a scalable rAAV process
Here we present the latest updates to our work developing a scalable start-to-finish rAAV process. We produce and purify several serotypes, optimizing each step along the way. The key for a successful…
Article
Top Process Development Trends for 2021 and a Look into 2022
However, the focus in 2021 shifted beyond the pandemic to optimization and scaling up adeno-associated virus (AAV) production, process workflows and considerations for messenger RNA (mRNA) therapeutic…
Article
Flexible Facilities for Viral Vector Manufacturing
Whereas for in-vivo gene therapies, using mostly AAV, the scale varies depending on the patient population, disease type, and route of injection, from a few 10 L up to 2000 L. For example, for Duchene…
Article
Ensuring Viral Safety of Viral Vaccines and Vectors
In adeno-associated virus (AAV) processes, any replication-competent helper adenovirus must be inactivated and removed during downstream purification. AAV particles can resist heating at 52 ⁰C for 1…
Article
rAAV Production Using HEK293 Cell Line and Transfection Medium
Improving the performance of a scalable AAV process in Xcellerex™ XDR-10 and XDR-200 bioreactor using HyClone™ peak expression medium.
LEARN MORE >>
Article
Optimizing capture and polishing steps in an rAAV purification process
In this article, we show how we developed an efficient purification process for recombinant AAV (rAAV). The chromatography purification described includes affinity capture to maxi…
Article
The Challenge of Disruptive Technologies in Bioprocessing
Thermo Fisher Scientific has commercialized three POROS CaptureSelect AAV affinity resins to establish industrialized platforms for the purification of adeno-associated virus (AAV). The move is meant …
Article
Q&As with Industry Leaders
…ent & Strategy, Cytiva
Insights and Strategies for Successful Development of Scalable AAV Processes: Part 2 of 2
Anki Magnusson, Staff Research Engineer, Protein and Viral Production, C…
Article
What is process development?
And ultracentrifugation to separate empty from full capsids of adeno-associated virus (AAV) does not scale well. Consider scalability from the start to avoid the need to rework your process.
And…
Article
From cells to purified capsids: How to develop a scalable rAAV process
In this webinar we present the latest updates to our work developing a scalable start-to-finish rAAV process. We produce and purify several serotypes, optimizing each step along the way. The key for a…